Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals
Status:
Completed
Trial end date:
2017-01-18
Target enrollment:
Participant gender:
Summary
The project will have two tracks, one for participants who are currently taking
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or E/C/F/tenofovir
alafenamide (E/C/F/TDF or E/C/F/TAF) single-tablet regimen* (STR) (Track A) and one for
participants who will begin therapy with E/C/F/TDF or E/C/F/TAF STR during the study (Track
B).
Participants will take E/C/F/TDF and/or E/C/F/tenofovir alafenamide fumarate (E/C/F/TAF)
STR** (if available) for 24 weeks.
*Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and
300 mg of tenofovir disoproxil fumarate.
**Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine,
and 10 mg of tenofovir alafenamide fumarate.